» Articles » PMID: 12071785

Causal Association in Pharmacovigilance and Pharmacoepidemiology: Thoughts on the Application of the Austin Bradford-Hill Criteria

Overview
Journal Drug Saf
Specialties Pharmacology
Toxicology
Date 2002 Jun 20
PMID 12071785
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The methods used for the evaluation of drug safety signals (including major signals leading to withdrawal of products from the market) are inconsistent and sometimes of poor quality. While the assessment of the safety of medicines needs to consider specific issues such as drug interactions and variation in compliance, the general principles, which are used to study environmental hazards, can be applied for this purpose. The criteria proposed by Sir Austin Bradford-Hill more than 35 years ago for attributing disease causation to environmental factors have been used widely in epidemiology, are applicable to pharmacovigilance and pharmacoepidemiology. The Austin Bradford-Hill criteria include strength, consistency, specificity, temporality, biological gradient, plausibility, coherence, experimental evidence and analogy. The paper reviews each of these criteria with emphasis on pharmacovigilance and pharmacoepidemiology and with some examples. The application of the Austin Bradford-Hill criteria to the evaluation of causal association in pharmacovigilance and pharmacoepidemiology is very useful. However, it requires understanding of the limitations of the data, such as, under-reporting, poor quality of information from third parties and misclassification. Further work is required to develop strategies to handle these limitations.

Citing Articles

Investigating Drug-Induced Thyroid Dysfunction Adverse Events Associated With Non-Selective RET Multi-Kinase Inhibitors: A Pharmacovigilance Analysis Utilizing FDA Adverse Event Reporting System Data.

Meng Z, Song L, Wang S, Duan G Clin Epidemiol. 2025; 17:87-104.

PMID: 39989882 PMC: 11844211. DOI: 10.2147/CLEP.S494215.


Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database.

Xiang H, Ma Y, Luo X, Guo J, Yao M, Liu Y Neurotherapeutics. 2024; 22(1):e00474.

PMID: 39482180 PMC: 11742624. DOI: 10.1016/j.neurot.2024.e00474.


The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study.

Cheng Y, Chen Y, Zhao X, Mou F, Wang W, Qian R Front Pharmacol. 2024; 15:1423075.

PMID: 39045047 PMC: 11263075. DOI: 10.3389/fphar.2024.1423075.


The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.

Fusaroli M, Salvo F, Begaud B, Alshammari T, Bate A, Battini V Drug Saf. 2024; 47(6):585-599.

PMID: 38713347 PMC: 11116264. DOI: 10.1007/s40264-024-01423-7.


Indapamide-Induced Rhabdomyolysis: An Evaluation of Case Reports in VigiBase Using the Bradford Hill Criteria.

Yue Q, Caduff-Janosa P Drugs Real World Outcomes. 2022; 9(2):189-198.

PMID: 35235186 PMC: 9114225. DOI: 10.1007/s40801-022-00295-6.


References
1.
Bate A, Lindquist M, Edwards I, Olsson S, Orre R, Lansner A . A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54(4):315-21. DOI: 10.1007/s002280050466. View

2.
Mackay F, Wilton L, Pearce G, Freemantle S, Mann R . Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997; 38(8):881-6. DOI: 10.1111/j.1528-1157.1997.tb01252.x. View

3.
Ansell P, Bull D, Roman E . Childhood leukaemia and intramuscular vitamin K: findings from a case-control study. BMJ. 1996; 313(7051):204-5. PMC: 2351604. DOI: 10.1136/bmj.313.7051.204. View

4.
Wright P . Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975; 1(5958):595-8. PMC: 1672788. DOI: 10.1136/bmj.1.5958.595. View

5.
Dixon J . Hormone replacement therapy and the breast. BMJ. 2001; 323(7326):1381-2. PMC: 1121850. DOI: 10.1136/bmj.323.7326.1381. View